The Calculated Objective Response Rate (ORR) of 97% from Post-Hoc Analysis of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma (BCC): (ORR) of 97% from Post-Hoc Analysis of a Phase 2 to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma (BCC). J of Skin. 2025;9(2):s565. doi:10.25251/skin.10.supp.565